×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PAVM – pavmed inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PAVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/10
08:00 am
pavm
PAVmed (PAVM) had its price target lowered by Ascendiant Capital Markets from $510.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
PAVmed (PAVM) had its price target lowered by Ascendiant Capital Markets from $510.00 to $65.00. They now have a "buy" rating on the stock.
4/9
08:18 am
pavm
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/8
09:52 pm
pavm
How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment [Yahoo! Finance]
Low
Report
How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment [Yahoo! Finance]
4/4
01:04 am
pavm
PAVmed (PAVM) was upgraded by Wall Street Zen from "sell" to "hold".
Low
Report
PAVmed (PAVM) was upgraded by Wall Street Zen from "sell" to "hold".
4/2
08:32 am
pavm
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio [Yahoo! Finance]
Medium
Report
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio [Yahoo! Finance]
4/2
08:21 am
pavm
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio [TheStreet.com]
Medium
Report
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio [TheStreet.com]
4/2
08:01 am
pavm
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medium
Report
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
3/30
07:19 pm
pavm
PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth Initiatives [Yahoo! Finance]
Low
Report
PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth Initiatives [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/14
04:06 pm
pavm
Form SCHEDULE 13G/A PAVmed Inc. Filed by: Tasso Partners, LLC
Low
Report
Form SCHEDULE 13G/A PAVmed Inc. Filed by: Tasso Partners, LLC
4/13
04:11 pm
pavm
Form 4 PAVmed Inc. For: Apr 02 Filed by: Lee Victoria Tou-ho
Low
Report
Form 4 PAVmed Inc. For: Apr 02 Filed by: Lee Victoria Tou-ho
4/13
04:08 pm
pavm
Form 3 PAVmed Inc. For: Mar 24 Filed by: Lee Victoria Tou-ho
Low
Report
Form 3 PAVmed Inc. For: Mar 24 Filed by: Lee Victoria Tou-ho
4/13
11:13 am
pavm
Form SCHEDULE 13G PAVmed Inc. Filed by: Scopia Holdings LLC
Low
Report
Form SCHEDULE 13G PAVmed Inc. Filed by: Scopia Holdings LLC
4/9
08:57 pm
pavm
Form SCHEDULE 13D PAVmed Inc. Filed by: Aklog Lishan
Low
Report
Form SCHEDULE 13D PAVmed Inc. Filed by: Aklog Lishan
4/8
08:40 pm
pavm
Form SCHEDULE 13G PAVmed Inc. Filed by: NAGELBERG DAVID S
Low
Report
Form SCHEDULE 13G PAVmed Inc. Filed by: NAGELBERG DAVID S
4/8
06:09 pm
pavm
Form SCHEDULE 13G PAVmed Inc. Filed by: Dols Scott V.
Low
Report
Form SCHEDULE 13G PAVmed Inc. Filed by: Dols Scott V.
4/6
09:46 pm
pavm
Form 3 PAVmed Inc. For: Mar 27 Filed by: Tasso Partners, LLC
Medium
Report
Form 3 PAVmed Inc. For: Mar 27 Filed by: Tasso Partners, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
PAVmed to Hold Business Update Conference Call on April 9, 2020
19.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
TOP News Decliners
1/13
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
-15.5%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: